Skip to main content
Premium Trial:

Request an Annual Quote

Quest, Hologic Enter Deal to Improve Women's Health

NEW YORK (GenomeWeb News) – Quest Diagnostics and Hologic today announced an alliance aimed at improving women's health.

Under the terms of the five-year strategic alliance, Quest will more broadly offer testing based on Hologic's Aptima products. The two firms will also co-develop and promote advanced diagnostics solutions for women's health.

The alliance focuses mainly on clinical areas critical to women's health, and Quest will transition to a wider offering of services on the Aptima product line. They include US Food and Administration-approved or -cleared assays for HPV, HPV genotyping, chlamydia, gonorrhea, and Trichomonas vaginalis. Quest will continue using Hologic's ThinPrep liquid-based cytology products and offering the Aptima HPV mRNA-based assay nationally, it and Hologic said.

Additionally, the two companies will investigate opportunities to develop new diagnostics targeting women's health and implement joint programs to promote women's health issues with medical associations and patient advocacy groups, as well as sponsor research.

"This alliance will enhance the ability of Quest Diagnostics to deliver state-of-the-art testing methods and specialized expertise in women's health diagnostic information services," Quest President and CEO Steve Rusckowski said in a statement. He added that today's deal builds on a long relationship between it and Hologic aimed at "delivering solutions that address the clinical challenges facing obstetricians and gynecologists in treating women.

"This collaboration also promises to increase the range of capabilities for advancing the health of women for both companies," he said.

Financial and other terms were not disclosed.

"Quest Diagnostics' strong capabilities in diagnostic information services and laboratory and interpretive consulting, when combined with Hologic's technical expertise and product excellence, holds the potential for us to develop new capabilities for serving unmet clinical needs for women in other areas of cancer detection," Hologic President and CEO Rob Cascella said.